Research outputs per year
Research outputs per year
Description
This copy of the Supplementary Material is subject to the same embargo as the post-print and will be available here from 06/02/21.
Content:
Model parameterization
Vehicle and enzalutamide:
-In vitro experiments
Figures SMM1 & SMM2
-In vivo experiments (under skin)
Figures SMM3 & SMM4
Mathematical model for combo therapies: enzalutamide-everolimus or
enzalutamide-cabazitaxel
Everolimus:
-From in vitro experiments
Figures SMM5 & SMM6
-In vivo experiments (under skin)
Figure SMM7
Cabazitaxel:
-In vitro experiments
Figures SMM8 & SMM9
-In vivo experiments (under skin)
Figure SMM10
Sensitivity Analysis
Content:
Model parameterization
Vehicle and enzalutamide:
-In vitro experiments
Figures SMM1 & SMM2
-In vivo experiments (under skin)
Figures SMM3 & SMM4
Mathematical model for combo therapies: enzalutamide-everolimus or
enzalutamide-cabazitaxel
Everolimus:
-From in vitro experiments
Figures SMM5 & SMM6
-In vivo experiments (under skin)
Figure SMM7
Cabazitaxel:
-In vitro experiments
Figures SMM8 & SMM9
-In vivo experiments (under skin)
Figure SMM10
Sensitivity Analysis
| Date made available | 6 Feb 2020 |
|---|---|
| Publisher | University of Portsmouth |
Research output
- 1 Article
-
Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer
Cerasuolo, M., Maccarinelli, F., Coltrini, D., Mokhtar, A., Marolda, V., Ghedini, G. C., Rezzola, S., Giacomini, A., Triggiani, L., Kostrzewa, M., Verde, R., Paris, D., Melck, D., Presta, M., Ligresti, A. & Ronca, R., 1 Apr 2020, In: Cancer Research. 80, 7, p. 1564-1577 14 p., 0.Research output: Contribution to journal › Article › peer-review
Open AccessFile669 Downloads (Pure)
Cite this
- DataSetCite